newsletter masthead
May 25, 2018
MEMBER/CENTER HIGHLIGHTS
Can the genetic makeup of their cancers predict how patients with lung cancer will respond to radiation therapy? And can this information be used to advance a genetically guided strategy for patients with these tumors? Cleveland Clinic researcher, radiation oncologist, and Case CCC member  Mohamed Abazeed, MD, PhD, has been awarded a $2 million grant from the National Cancer Institute (NCI) to delve into those and other related questions.

Dr. Abazeed's overall objective for this award is to identify new genetic markers calibrated on the basis of radiation therapy effectiveness and new drug-radiation therapy strategies that more precisely and effectively target the most resistant lung tumors to radiation. more>
Colon Cancer Cells Use Mysterious RNA Strands to Avoid Cell Death
Researchers from the Case Comprehensive Cancer Center have discovered how unusually long strands of RNA help colon cancer cells avoid death, allowing unregulated growth. Unlike other RNAs, the intriguing strands do not appear to encode proteins and are termed "long non-coding RNAs" or "lincRNAs." A new study showed some lincRNAs could be targeted by drug developers to halt colon cancer.

In a new study published in  Scientific Reports [Forrest, Sci Reports, 2018], researchers compared lincRNA levels inside tumor cells, to levels inside healthy colon cells. They found over 200 lincRNAs at significantly different levels inside the tumor cells as compared to normal cells. One in particular, called lincDUSP, was overexpressed in 91 percent of the tumor samples. A few tumors had more than fifteen times the normal amount of lincDUSP. The significant increase suggested this mysterious, and previously uncharacterized, RNA could be cancer-causing. 

Ahmed Khalil "Our work demonstrates that not only protein-coding genes but also non-coding genes contribute to colon cancer progression," says Ahmad Khalil, PhD, senior author, assistant professor of genetics and genome sciences at Case Western Reserve University School of Medicine, and member of the Case Comprehensive Cancer Center. "LincRNAs could be exploited as direct drug targets in this and other human diseases."

Co-authors on this study include Megan E. Forrest, Alina Saiakhova, Lydia Beard, David A. Buchner, Peter C. Scacheri, Thomas LaFramboise, and Sanford Markowitz. This research was partially supported by the Case Comprehensive Cancer Center Integrated Genomics Shared Resource and Cytometry and Microscopy Shared Resource.  more>
Reducing Cholesterol Could Enhance T-Cell Cancer Immunotherapy
Cleveland Clinic researchers have demonstrated for the first time that lowering blood cholesterol levels could enhance the success of a specific type of T-cell immunotherapy in fighting cancer [ Ma, J Exp Med, 2018].

Qing Yi The team, led by  Qing Yi, MD, PhD of the Cleveland Clinic and Case Comprehensive Cancer Center, studied T-cell transfer, which has shown great success in recent years. Dr. Yi previously showed that a specific subset of T-cells, called Tc9 cells, have stronger anti-tumor effects than other types of T-cells. In the new study, they determined the mechanisms that give Tc9 cells their anti-cancer properties and how these mechanisms might be tweaked to enhance immunotherapy. 

Using gene profiling, the researchers discovered that Tc9 cells had much lower levels of intracellular cholesterol than other T-cells. They hypothesized that the reduced cholesterol levels might contribute to the cells' anti-tumor effects. Indeed, when cholesterol-lowering drugs were administered to the cells, anti-cancer pathways were turned on (IL-9 expression and NF-KB signaling). Furthermore, they showed in a tumor-bearing preclinical model that reducing cholesterol levels prior to immunotherapy led to greater concentrations of IL-9 and better cancer-killing success.  more>
NEWS FROM NCI
Annual Report to the Nation
Annual Report to Nation The Annual Report to the Nation on the Status of Cancer was released on May 22, 2018. The first part of the report focused on national cancer statistics. The report found that cancer mortality rates for men, women, and children continue to decline. In addition, The overall cancer incidence rate for children under age 14 increased, with variance by racial/ethnic group. Male  cancer incidence rates continue to decrease, with prostate cancer showing the greatest decrease. Cancer incidence rates in women  remained stable, with colorectal cancer showing the greatest decrease. Liver cancer showed the greatest increase in both men and women; this may be attributed to rising obesity rates. The rate of new lung cancer cases continues to decrease for both men and women as does the smoking rate, but lung cancer is still the second most common cancer for both men and women. 

MARK YOUR CALENDARS
VeloSano 5: Get Involved! 
VeloSano logo Spring is here, and it's time to start building momentum for VeloSano 5! Remember, a ll of the funds raised through VeloSano support cancer research right here in Cleveland. 

Getting involved is easy. Your help and support is appreciated:
Contact Team Captains Mary Wright ( maw143@case.edu) or Caroline El Sanadi ( cee17@case.eduwith any questions! 
Race for the Place 2018
Race for the Place 2018 Jun 3, 2018 | Beachwood Place
Walk or run with the  Case CCC team at the Race for the Place , June 3, 2018. This great event helps The Gathering Place to offer services to anyone touched by cancer, no matter their economic situation. Anyone and everyone is welcome to join our team. If you can't make the Race in person, please consider making a donation to support our efforts. Hope to see you there! Questions: Contact Captain Gillian Irwin ( gmi@case.edu ). 
Cancer Center Scientific Series: VeloSano Pilot Awardees
Jun 4, 2018, 5-7p  | Wolstein Research Bldg
VeloSano logo Join us for the next Cancer Center Scientific Series and hear updates from recipients of VeloSano pilot awards. Presentations will be followed by a reception. 

Mark Jackson, PhD
A high-throughput screen for inhibitors of cancer stem cell plasticity

Julian Kim, MD
Development of intravenously injectable β-glucan treatment for regulating granulocytic myeloid-derived suppressive cells

Shigemi Matsuyama, PhD
Development of new type of therapeutics selectively targeting Bax or Bak

Alvin Schmaier, MD
Tyrosine kinase inhibitors and cardiovascular events in CML

Andrew Sloan, MD
Hematologic biomarkers of treatment response & recurrence in patients with glioblastoma

Zhenghe John Wang, PhD
Develop GPT2 inhibitors to target PI3KCA-mutated colorectal cancers 

Youwei Zhang, PhD
Roles of UbcH7 in tumorigenesis and therapy response 

Lan Zhou, MD, PhD
Mediates immune-suppressive microenvironment in serrated pathway of colon carcinogenesis 

CSC 2018 - web banner

Cancer Stem Cell Conference
Aug 6-8, 2018 | Tinkham Veale 

Call for Abstracts Deadline Extended: May 25
Discounts for early registration through May 31

The Case Comprehensive Cancer Center (Case CCC) and National Center for Regenerative Medicine (NCRM) invite you to Cancer Stem Cell Conference (CSC 2018)! Now in it's third year, CSC 2018 will feature renowned thought leaders in the field of cancer stem cell research. This conference is guaranteed to offer cutting-edge keynote presentations from a variety of niches within the field. Join world-class investigators for this 3-day summit and network with scientists and clinicians advancing cancer stem cell research and therapeutic applications.

Conference Highlights
  • The agenda will integrate invited talks from thought leaders in the CSC field with short talks from early-stage investigators and trainees selected from submitted abstracts.
  • Pre-conference career development workshop for junior faculty and trainees
    • Meet the Editors: Natalie Cain, PhD (CellReports), Mark Landis, PhD (CancerDiscovery) and Teodoro Pulvirenti, PhD(JEM)
    • Discussion of NIH grants: Michael Espey, PhD (NCI) and Michelle McGuirl, PhD (NIH)
  • Young Investigator Awards available to support travel for senior trainees or junior faculty (less than 5 years from their first independent position). Submit your abstracts by May 15 to be eligible. 
  • Opportunity to share ideas with world-class investigators in stem cell research. 2016 CSC was attended by over 300 from 20 countries and 25 U.S. states. This year's conference is on track to attract a similar crowd of colleagues.
Keynote Speakers
  • Norman E. 'Ned' Sharpless, MD (NCI)
  • John S. Condeelis, PhD (Einstein)
  • Irving Weissman, MD (Stanford)
  • Zena Werb, PhD (UCSF)
IN THE NEWS
Think - Spring 2018
Cancers hit certain populations harder than others, and researcher Monica Webb Hooper, director of the Office of Cancer Disparities Research at the Case Comprehensive Cancer Center, wants to know why. 
News5Cleveland.com - May 21, 2018
Researchers are looking for 120,000 women nationwide to take part in a study that might lead to detecting cancer with a blood test  The Cleveland Clinic is teaming up with the Mayo Clinic, as well as several other hospitals across the country, for the STRIVE study. It's a study that will use advanced technology to look for small pieces of genetic material released into the blood by tumors..."This goes beyond breast cancer," said Dr. Stephen Grobmyer, Case Comprehensive Cancer Center, Director of the Breast Center at the Cleveland Clinic. "This would be a way to screen for not only breast cancer but other cancers with a blood test."
Case Western Reserve announces new partnership with Microsoft
Crain's Cleveland Business - May 18, 2018
Case Western Reserve University again will be working with Microsoft, this time on a project related to "quantum computing. Radiology professor and  Case Comprehensive Cancer Centermember  Mark Griswold and his team will work with quantum computing experts at Microsoft Quantum on the new collaboration. The goal will be to "improve the practical ways that MRI machines acquire information during scans," according to a news release.
MedPage Today - May 19, 2018
As currently envisioned for clinical practice, the IsoPSA would come into play whenever a patient has a "worrisome" PSA value. If the assay proved negative, a patient would be offered active surveillance. If the IsoPSA result suggested high-grade disease, MRI evaluation would follow. If negative, the patient would undergo conventional TRUS-guided biopsy, but if MRI supported the IsoPSA finding of high-grade disease, the patient would undergo  MRI-ultrasound fusion biopsy"The question is, what is the new training paradigm going to look like," said Eric Klein, MD, of the Cleveland Clinic and Case Comprehensive Cancer Center, and first author of the initial study of IsoPSA. "We know that PSA alone is only accurate about 60% of the time in terms of diagnosing prostate cancer and leads to overdiagnosis of low-grade prostate cancer."
FUNDING OPPORTUNITIES
Pew-Stewart Scholars for Cancer Research 
Internal Deadline: Jun 4, 2018
Pew Charitable Trusts The Pew Charitable Trusts have invited the Case CCC to nominate a single candidate for the 2019 Pew-Stewart Scholars for Cancer Research Program. To apply send your research project summary (1-page or less) and NIH Biosketch as a single PDF with "Pew-Stewart Scholar LOI" in the email header to Cindy  Rahn  at  clr30@case.edu  by  Jun 4, 2018   by  5p EST .  
NCI Cancer Prevention Fellowship Program (CPFP)
Deadline: Aug 25, 2018
NCI logo The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. 
American Association for Cancer Research (AACR)  

Deadline: Aug 1, 2018
AACR logo The AACR Team Science Award has been established by the AACR and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications. Proactive interaction between academic and industry researchers is particularly crucial to continue progress and accelerate drug development.

The team selected to receive the Thirteenth AACR Team Science Award will collectively be awarded an honorarium of $50,000 and be recognized during the AACR Annual Meeting 2019 in Atlanta, Georgia, USA (March 30-April 3, 2019). The represented institutions will be cited at the AACR Annual Meeting for their leadership role in fostering team science in cancer research.

Deadline: Sep 12, 2018
The prestigious Pezcoller Foundation-AACR International Award for Cancer Research was established in 1997 to annually recognize a scientist of international renown:
  • who has made a major scientific discovery in basic cancer research OR who has made significant contributions to translational cancer research;
  • who continues to be active in cancer research and has a record of recent, noteworthy publications; and
  • whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer.
The award is intended to honor an individual scientist. However, more than one scientist may be co-nominated and selected to share the award when their investigations are closely related in subject matter and have resulted in work that is worthy of the award.
The award consists of an unrestricted honorarium of €75,000, a commemorative plaque, and full support to the winner and a guest to attend the AACR Annual Meeting. The winner of the 22nd Annual Pezcoller Foundation-AACR International Award for Extraordinary Achievement Cancer Research will give an award lecture at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA (March 30-April 3, 2019).

NIH BULLETIN- Notices and Funding Opportunities
rfas 
Program Announcements
Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 - Clinical Trial Optional)(PAR-18-801)

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 - Clinical Trial Optional)(PAR-18-802)

NIH Directors New Innovator Award Program (DP2 - Clinical Trial Optional)(RFA-RM-18-008)
 
NIH Directors Transformative Research Award (R01 - Clinical Trial Optional)(RFA-RM-18-009) 
IN THIS ISSUE
EVENTSevents
Tues, May 30
Radiation Oncology Grand Rounds 
Musaddiq Awan, MD
PGY-5 Physician Resident, Radiation Oncology, UHCMC
"Patient selection for laryngeal preservation"
8:10a Lerer B-151

Frontiers in Biological Sciences Lecture Series
Andrew Weyrich, PhD
Vice President for Research; President, Internal Medicine; HA & Edna Benning Presidential Endowed Chair
University of Utah
"Translational pathways in megakaryocytes and platelets"
3p Robbins E301
Thurs, May 31
Developmental Therapeutics Journal Club
9a R4-013 Cleveland Clinic
Fri, Jun 1
TCI Grand Rounds
Robert Timmerman, MD
UT Southwestern
"SAbRs are mightier than scalpels"
8a CA5-120 Cleveland Clinic
Sun, Jun 3
Race for the Place
8-11a Beachwood Place Mall
Mon, Jun 4
Cancer Center Chalk Talk
Richard Lee, MD
Associate Professor, Medicine, CWRU/UH
1p WRB 3-136

Tumor Immunology and Immunotherapy Meeting
4p WRB 3-136

Cancer Center Scientific Series: VeloSano
5-7p WRB 1-413
Thurs, Jun 7
Developmental Therapeutics Journal Club
9a R4-013 Cleveland Clinic
Fri, Jun 8
Taussig Cancer Institute Grand Rounds
Stefan Klek; Brian Rini, MD; Ahmad Tarhini, MD;  Manmeet Ahluwalia, MD
"ASCO oral presentations"
9a CA5-120 Cleveland Clinic

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285